ライフサイエンスコーパス: ibritumomab tiuxetan

1 avasation of large molecules (e.g., [(90)Y]Y-ibritumomab tiuxetan).

2 patients using (131)I-tositumomab and (90)Y-ibritumomab tiuxetan.

3 at of control groups who did not receive 90Y ibritumomab tiuxetan.

4 apy given to patients who relapsed after 90Y ibritumomab tiuxetan.

5 on was the primary toxicity noted with (90)Y ibritumomab tiuxetan.

6 lar to that in patients not treated with 90Y ibritumomab tiuxetan.

7 tients (50 eligible patients) received (90)Y-ibritumomab tiuxetan.

8 ovel conditioning regimen combining NMA with ibritumomab tiuxetan.

9 ntravenously administered (111)In- and (90)Y-ibritumomab tiuxetan.

10 Abs) (131)iodine-tositumomab and (90)yttrium-ibritumomab tiuxetan.

11 weight-based dosing regimen used with (90)Y-ibritumomab tiuxetan.

12 (2-24 h) after the administration of (111)In-ibritumomab tiuxetan.

13 /- 1.64 GBq (range, 0.42-7.54 GBq) for (90)Y-ibritumomab tiuxetan.

14 t 2-24 h after the administration of (111)In-ibritumomab tiuxetan.

15 the beta-emitting radiopharmaceutical (90)Y-ibritumomab tiuxetan.

16 e studies of outpatient treatment with (90)Y ibritumomab tiuxetan.

17 ion on five separate protocols that used 90Y ibritumomab tiuxetan 0.4 mCi/kg.

18 later with rituximab (250 mg/m(2)) and (90)Y ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]).

19 ioimmunotherapy with a reduced dose of (90)Y ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]; maximum 32

20 ubsequently performed a trial in which (90)Y-ibritumomab tiuxetan (0.4 mCi/kg) was added to the fluda

21 te peripheral blood B cells, then yttrium-90 ibritumomab tiuxetan (0.4 mCi/kg; maximum, 32 mCi) intra

22 odgkin's lymphoma received standard-dose 90Y ibritumomab tiuxetan (14.8 MBq/kg [0.4 mCi/kg]) followed

23 adioimmunotherapy for NHL (20 received (90)Y-ibritumomab tiuxetan; 18 received (131)I-tositumomab).

24 to treat was made after imaging with (111)In-ibritumomab tiuxetan (4.0% of all cases captured); 16 of

25 ximab (250 mg/m(2)) and injection of (111)In ibritumomab tiuxetan (5 mCi [185 MBq]) for dosimetry eva

26 An imaging/dosimetry dose of indium-111 ibritumomab tiuxetan (5 mCi) was injected after rituxima

27 Of the responders, 29.5% used only (90)Y-ibritumomab tiuxetan, 7.6% used only (131)I-tositumomab,

28 efficacy and toxicity of fractionated (90)Y-ibritumomab tiuxetan ((90)Y-IT) as initial therapy of fo

29 a multicenter phase II trial of (90)yttrium-ibritumomab-tiuxetan ((90)YIT) as first-line stand-alone

30 ted that when measuring all volumes of (90)Y-ibritumomab tiuxetan activity prescriptions, only a sing

31 = 150,000 cells/mm(3) for the standard (90)Y-ibritumomab tiuxetan administered dose (15 MBq/kg [0.4 m

32 = 100,000 cells/mm(3) for the reduced (90)Y-ibritumomab tiuxetan administered dose (7.4-11 MBq/kg [0

33 Both ibritumomab tiuxetan administered doses were preceded by

34 on absorbed doses for (111)In- and for (90)Y-ibritumomab tiuxetan administered to 10 cancer patients

35 atients and their family members after (90)Y-ibritumomab tiuxetan administration.

36 pproximately 400) was not treated with (90)Y-ibritumomab tiuxetan after imaging with (111)In-ibritumo

37 single-center clinical experience with (90)Y-ibritumomab tiuxetan and (131)I-tositumomab for therapy

38 d not significantly differ between the (90)Y-ibritumomab tiuxetan and (131)I-tositumomab groups.

39 (mean +/- SD, 3.418 +/- 1.49) and that (90)Y-ibritumomab tiuxetan and (131)I-tositumomab were expensi

40 Both (90)Y-ibritumomab tiuxetan and (131)I-tositumomab were well to

41 n 57% and 56% of patients treated with (90)Y-ibritumomab tiuxetan and (131)I-tositumomab, respectivel

42 reports of the efficacy and safety of (90)Y-ibritumomab tiuxetan and (131)I-tositumomab, these thera

43 both 14-27 days before treatment with (90)Y-ibritumomab tiuxetan and 4-6 months after treatment.

44 enters, were administered the tracer (111)In-ibritumomab tiuxetan and assessed using planar scintilla

45 dministration approval for marketing - Y(90) ibritumomab tiuxetan and I(131) tositumomab, given as th

46 The single-agent activity of (90)Y-ibritumomab tiuxetan and its favorable safety profile wa

47 e declines in platelet counts than did (90)Y-ibritumomab tiuxetan and may be a more appropriate choic

48 nse (CR) rates were 30% and 16% in the (90)Y ibritumomab tiuxetan and rituximab groups, respectively

49 ared with previously published dosimetry for ibritumomab tiuxetan and the product package insert.

50 (90)Y- and (131)I-anti-CD20 antibodies (ibritumomab tiuxetan and tositumomab, respectively) have

51 d more frequently after treatment with (90)Y-ibritumomab tiuxetan and was associated with prolongatio

52 With the approval of (90)Y-ibritumomab tiuxetan, and based on the results of numero

53 d and Drug Administration has approved (90)Y-ibritumomab tiuxetan anti-B-cell NHL mAb as the first co

54 (111)In- and (90)Y-ibritumomab tiuxetan are labeled at commercial radiophar

55 We hypothesized that (9)(0)Y-ibritumomab tiuxetan-based NMAT would facilitate early c

56 itumomab tiuxetan after imaging with (111)In-ibritumomab tiuxetan, because of altered biodistribution

57 tic regimen in patients treated with (111)In-ibritumomab tiuxetan between March 27, 2002, and March 3

58 imab to clear peripheral B-cells and improve ibritumomab tiuxetan biodistribution.

59 We conclude that high-dose 90Y-ibritumomab tiuxetan can be combined safely with high-do

60 CHOP given for four cycles followed by (90)Y-ibritumomab tiuxetan compared favorably with historical

61 (90)Y-ibritumomab tiuxetan consists of a murine monoclonal ant

62 with 3 cycles of CHOP plus IFRT followed by ibritumomab tiuxetan consolidation had outcomes that com

63 313 trial, we evaluated the impact of adding ibritumomab tiuxetan consolidation to 3 cycles of standa

64 The median 90Y-ibritumomab tiuxetan dose was 71.6 mCi (2649.2 MBq; rang

65 ived 0.4 mCi/kg (maximum, 32 mCi/kg) (9)(0)Y-ibritumomab tiuxetan, fludarabine, and 2 Gy total body i

66 ative; and for non-CMR patients, one dose of ibritumomab tiuxetan followed by standard RM.

67 simetry (day -21) with 5 mCi (185 MBq) 111In-ibritumomab tiuxetan following 250 mg/m2 rituximab, foll

68 e biodistribution and one dose of indium-111 ibritumomab tiuxetan for imaging and dosimetry.

69 eferring hematooncologist now includes (90)Y-ibritumomab tiuxetan for refractory low-grade follicular

70 rituximab, 250 mg/m(2), followed by (111)In-ibritumomab tiuxetan, for imaging, on day 1 and a dose o

71 1 and a dose of rituximab followed by (90)Y-ibritumomab tiuxetan, for therapy, on day 7, 8, or 9.

72 he safety and efficacy of yttrium-90 ((90)Y) ibritumomab tiuxetan given as consolidation of complete

73 rophil count nadir was shorter for the (90)Y-ibritumomab tiuxetan group than for the (131)I-tositumom

74 radioimmunotherapy was greater in the (90)Y-ibritumomab tiuxetan group than in the (131)I-tositumoma

75 ion of response was 14.2 months in the (90)Y ibritumomab tiuxetan group versus 12.1 months in the con

76 ORR was 80% for the (90)Y ibritumomab tiuxetan group versus 56% for the rituximab

77 The predominant toxicity of 90Y ibritumomab tiuxetan has been myelosuppression, and conc

78 Yttrium-90 ibritumomab tiuxetan (IDEC-Y2B8) is a murine immunoglobu

79 t-Line Indolent Trial of yttrium-90 ((90)Y) -ibritumomab tiuxetan in advanced-stage follicular lympho

80 conducted a phase 1/2 trial of high-dose 90Y-ibritumomab tiuxetan in combination with high-dose etopo

81 r (131)I-tositumomab and the liver for (90)Y-ibritumomab tiuxetan in myeloablative NHL treatment regi

82 he safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with relapsed or refrac

83 This study evaluated ibritumomab tiuxetan in the treatment of rituximab-refra

84 In summary, (90)Y-ibritumomab tiuxetan introduces (90)Y into clinical prac

85 90Y-ibritumomab tiuxetan is a novel radioimmunotherapeutic a

86 Ibritumomab tiuxetan is an anti-CD20 murine IgG1 kappa m

87 (90)Y-ibritumomab tiuxetan is dosed on the basis of the patien

88 transplantation after prior therapy with 90Y ibritumomab tiuxetan is feasible and reasonably well tol

89 emissions associated with the therapy, (90)Y-ibritumomab tiuxetan is routinely administered on an out

90 Reduced-dose ibritumomab tiuxetan is safe and well tolerated and has

91 Radioimmunotherapy with (90)Y ibritumomab tiuxetan is well tolerated and produces stat

92 Dose-escalated (90)Y ibritumomab tiuxetan may be safely combined with high-do

93 ents received 131I-tositumomab (n=23) or 90Y-ibritumomab tiuxetan (n=10) and underwent 18F-FDG PET/CT

94 ioimmunotherapy with 131I-tositumomab or 90Y-ibritumomab tiuxetan not only induces high response rate

95 administered dose of 185 MBq (5 mCi) (111)In-ibritumomab tiuxetan on day 0, evaluated with dosimetry,

96 dose of 7.4-15 MBq/kg (0.2-0.4 mCi/kg) (90)Y-ibritumomab tiuxetan on day 7.

97 roved anti-CD20 radioimmunoconjugates ((90)Y-ibritumomab tiuxetan or (131)I-tositumomab) have had enc

98 Ibritumomab tiuxetan produces durable responses in patie

99 Ibritumomab tiuxetan radioimmunotherapy is effective in

100 Ibritumomab tiuxetan radioimmunotherapy targets the same

101 involved field radiation therapy followed by ibritumomab tiuxetan radioimmunotherapy.

102 genous leukemia (t-AML) after treatment with ibritumomab tiuxetan radioimmunotherapy.

103 Yttrium Y 90 ibritumomab tiuxetan, recently approved by the Food and

104 on-Hodgkin's lymphoma (NHL) treated with the ibritumomab tiuxetan regimen in registration and compass

105 The ibritumomab tiuxetan regimen included an infusion of rit

106 An ibritumomab tiuxetan regimen was initiated 3 to 6 weeks

107 ear to be increased after treatment with the ibritumomab tiuxetan regimen.

108 alone, at which one may underestimate (90)Y-ibritumomab tiuxetan response by considering inactive re

109 kinetic data from 4 clinical trials of (90)Y-ibritumomab tiuxetan RIT for relapsed or refractory B-ce

110 Single-dose (90)Y ibritumomab tiuxetan RIT has an acceptable safety profil

111 ment by NHL can be treated safely with (90)Y-ibritumomab tiuxetan RIT on the basis of a fixed, weight

112 use of a procedure for radiolabeling (111)In-ibritumomab tiuxetan that differed from that in the pres

113 The ibritumomab tiuxetan therapeutic regimen consists of a d

114 s to verify completion of treatment with the ibritumomab tiuxetan therapeutic regimen in patients tre

115 of an estimated 1,144-1,192 patients in whom ibritumomab tiuxetan therapy was initiated (case capture

116 antation with stem cells collected after 90Y ibritumomab tiuxetan therapy.

117 compared to patients who did not receive 90Y ibritumomab tiuxetan, there was no significant differenc

118 g/m2 rituximab, followed a week later by 90Y-ibritumomab tiuxetan to deliver a target dose of 1000 cG

119 Adding 90Y ibritumomab tiuxetan to high-dose BEAM with autologous s

120 The addition of (9)(0)Y-ibritumomab tiuxetan to NMAT is safe and yields early re

121 ad experienced disease progression after 90Y ibritumomab tiuxetan treatment and received subsequent t

122 The ibritumomab tiuxetan treatment regimen consisted of pret

123 ble superior assessment of response to (90)Y-ibritumomab tiuxetan treatment than the use of CT alone,

124 131I-tositumomab and those who received 90Y-ibritumomab tiuxetan was demonstrated (-31%+/-51% vs. -4

125 The therapeutic dose of (90)Y ibritumomab tiuxetan was followed by high-dose BEAM and

126 ies, (131)iodine-tositumomab and (90)yttrium-ibritumomab tiuxetan, were FDA-approved more than a deca

127 icroL received a dose of 0.4 mCi/kg of (90)Y-ibritumomab tiuxetan, whereas those with a platelet coun

128 novel radioimmunotherapy yttrium-90 ((90)Y) ibritumomab tiuxetan with a control immunotherapy, ritux

129 y and efficacy of combining yttrium-90 (90Y) ibritumomab tiuxetan with high-dose carmustine, cytarabi

130 d at 2-24 h and at 48-72 h after the (111)In-ibritumomab tiuxetan, with an optional third scan at 90-

131 Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) and tositumomab-131I (Bex

132 eviously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT)

133 Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceutical, San

134 ssion (CR) before transplant by adding (90)Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen.

135 90 ((90)Y)-labeled anti-CD20 antibody ((90)Y ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corp